Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis

Journal of Allergy and Clinical Immunology

Volumn 106, Issue 2, 2000, Pages 253-259

  Ädelroth, Ellinor ^a   Rak, Sabina ^b   Haahtela, Tari ^c   Aasand, Gunbjörn ^d   Rosenhall, Leif ^e   Zetterstrom, Olle ^f   Byrne, Aidan ^g   Champain, Kate ^g   Thirlwell, Jackie ^g   Cioppa, Giovanni Della ^g   Sandström, Thomas ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d ENT Clinic   (Norway)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^g NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

Author keywords

Allergic rhinitis; Allergy; Anti IgE; IgE; Recombinant humanized mAb E25

Indexed keywords

ANTIHISTAMINIC AGENT; IMMUNOGLOBULIN E; MAB-E25; MONOCLONAL ANTIBODY; PLACEBO; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALLERGIC RHINITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; POLLEN; POLLEN ALLERGY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS; SKIN TEST;

EID: 0033836319     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2000.108310     Document Type: Article

References (28)

1. Variations in the prevalence of respiratory symptoms, self-reported asthma attacks arid use of asthma medication in the European Community Respiratory Health Survey (ECRHS)
2. World-wide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis and atopic eczema
3. Epidemiology of rhinitis and asthma
4. Epidemiology of the allergic diseases: Are they really on the increase?
5. Evidence for an increase in atopic disease and possible causes
6. The receptor with high affinity for immunoglobulin E
7. Activation of mast cells for mediator release through IgE receptors
8. The pharmacology and use of H1-receptor-antagonist drugs
9. The rationale for the use of topical corticosteroids in allergic rhinitis
10. Topical pharmacotherapy for allergic rhinitis: Nedocromil
11. Allergen immunotherapy: Therapeutic vaccines for allergic diseases
12. Humanization of an antibody directed against IgE
13. Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: Inhibition by a non-anaphylactogenic anti-IgE antibody
14. Therapeutic potential of anti IgE antibodies
15. Pollen-related allergy in Europe
16. Allergy and allergy-like symptoms in 1,050 medical students
17. Activation of B-lymphocytes during pollen season. Effect of immunotherapy
18. The effect of immunotherapy on eosinophil accumulation and production of eosinophil chemotactic activity in the lung of subjects with asthma during natural pollen exposure
19. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis
20. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis
21. Immediate hypersensitivity
22. Interpretation of rhinoconjunctivitis quality of life questionnaire data
23. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: Systematic review of randomised controlled trials
24. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects
25. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response
26. Treatment of allergic asthma with monoclonal anti-IgE antibody
27. Effect of aerolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects